Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors

被引:3
作者
Carmen Martin, M. [1 ]
Jimenez, Ana [1 ]
Ortega, Nuria [1 ]
Parrado, Alba [1 ]
Page, Isabel [1 ]
Isabel Gonzalez, M. [1 ]
Blanco-Peris, Lydia [1 ]
机构
[1] Ctr Hemoterapia & Hemodonac Castilla Y Leon, Valladolid, Castilla Y Leon, Spain
来源
PLOS ONE | 2022年 / 17卷 / 02期
关键词
COVID-19;
D O I
10.1371/journal.pone.0264124
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The vast majority of COVID-19 cases both symptomatic and asymptomatic develop immunity after COVID-19 contagion. Whether lasting differences exist between infection and vaccination boosted immunity is yet to be known. The aim of this study was to determine how long total anti-SARS-CoV2 antibodies due to past infection persist in peripheral blood and whether sex, age or haematological features can influence their lasting. Material and methods A series of 2421 donations either of SARS-CoV-2 convalescent plasma or whole blood from 1107 repeat donors from January 2020 to March 2021 was analysed. An automated chemiluminescence immunoassay for total antibodies recognizing the nucleocapsid protein of SARS-CoV-2 in human serum and plasma was performed. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings. Blood donation is allowed after a minimum of one-month post symptom's relapse. Donors were 69.7% males and their average age was 46. The 250 donors who had later donations after a positive one underwent further analysis. Both qualitative (positivity) and quantitative (rise or decline of optical density regarding consecutive donations) outcomes were evaluated. Results and discussion In 97.6% of donors with follow-up, anti-SARS-CoV-2 protein N total antibodies remained positive at the end of a follow-up period of 12.4 weeks median time (1-46, SD = 9.65) after the first positive determination. The blood group was not related to antibody waning. Lower lymphocyte counts and higher neutrophils would help predict future waning or decay of antibodies. Most recovered donors maintain their total anti-SARS-CoV-2 N protein antibodies for at least 16 weeks (at least one month must have been awaited from infection resolution to blood donation). The 10 individuals that could be followed up longer than 40 weeks (approximately 44 weeks after symptom's relapse) were all still positive.
引用
收藏
页数:12
相关论文
共 28 条
  • [11] Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays
    Kohmer, Niko
    Westhaus, Sandra
    Ruehl, Cornelia
    Ciesek, Sandra
    Rabenau, Holger F.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2020, 129
  • [12] A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity
    Legros, Vincent
    Denolly, Solene
    Vogrig, Manon
    Boson, Bertrand
    Siret, Eglantine
    Rigaill, Josselin
    Pillet, Sylvie
    Grattard, Florence
    Gonzalo, Sylvie
    Verhoeven, Paul
    Allatif, Omran
    Berthelot, Philippe
    Pelissier, Carole
    Thiery, Guillaume
    Botelho-Nevers, Elisabeth
    Millet, Guillaume
    Morel, Jerome
    Paul, Stephane
    Walzer, Thierry
    Cosset, Francois-Loic
    Bourlet, Thomas
    Pozzetto, Bruno
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (02) : 318 - 327
  • [13] Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
    Long, Quan-Xin
    Tang, Xiao-Jun
    Shi, Qiu-Lin
    Li, Qin
    Deng, Hai-Jun
    Yuan, Jun
    Hu, Jie-Li
    Xu, Wei
    Zhang, Yong
    Lv, Fa-Jin
    Su, Kun
    Zhang, Fan
    Gong, Jiang
    Wu, Bo
    Liu, Xia-Mao
    Li, Jin-Jing
    Qiu, Jing-Fu
    Chen, Juan
    Huang, Ai-Long
    [J]. NATURE MEDICINE, 2020, 26 (08) : 1200 - +
  • [14] Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
    Lozano-Ojalvo, Daniel
    Camara, Carmen
    Lopez-Granados, Eduardo
    Nozal, Pilar
    Del Pino-Molina, Lucia
    Yadira Bravo-Gallego, Luz
    Paz-Artal, Estela
    Pion, Marjorie
    Correa-Rocha, Rafael
    Ortiz, Alberto
    Lopez-Hoyos, Marcos
    Erro Iribarren, Marta
    Portoles, Jose
    Pilar Rojo-Portoles, Maria
    Ojeda, Gloria
    Cervera, Isabel
    Gonzalez-Perez, Maria
    Bodega-Mayor, Irene
    Montes-Casado, Maria
    Portoles, Pilar
    Perez-Olmeda, Mayte
    Oteo, Jesus
    Sanchez-Tarjuelo, Rodrigo
    Pothula, Venu
    Schwarz, Megan
    Brahmachary, Manisha
    Tan, Anthony Tanoto
    Le Bert, Nina
    Berin, Cecilia
    Bertoletti, Antonio
    Guccione, Ernesto
    Ochando, Jordi
    [J]. CELL REPORTS, 2021, 36 (08):
  • [15] Marongiu F, 2021, EUR REV MED PHARMACO, V25, P3886, DOI 10.26355/eurrev_202105_25956
  • [16] The age again in the eye of the COVID-19 storm: evidence-based decision making
    Martin, Maria C.
    Jurado, Aurora
    Abad-Molina, Cristina
    Orduna, Antonio
    Yarce, Oscar
    Navas, Ana M.
    Cunill, Vanesa
    Escobar, Danilo
    Boix, Francisco
    Burillo-Sanz, Sergio
    Vegas-Sanchez, Maria C.
    Jimenez-de Las Pozas, Yesenia
    Melero, Josefa
    Aguilar, Marta
    Sobieschi, Oana Irina
    Lopez-Hoyos, Marcos
    Ocejo-Vinyals, Gonzalo
    San Segundo, David
    Almeida, Delia
    Medina, Silvia
    Fernandez, Luis
    Vergara, Esther
    Quirant, Bibiana
    Martinez-Caceres, Eva
    Boiges, Marc
    Alonso, Marta
    Esparcia-Pinedo, Laura
    Lopez-Sanz, Celia
    Munoz-Vico, Javier
    Lopez-Palmero, Serafin
    Trujillo, Antonio
    Alvarez, Paula
    Prada, Alvaro
    Monzon, David
    Ontanon, Jesus
    Marco, Francisco M.
    Mora, Sergio
    Rojo, Ricardo
    Gonzalez-Martinez, Gema
    Martinez-Saavedra, Maria T.
    Gil-Herrera, Juana
    Cantenys-Molina, Sergi
    Hernandez, Manuel
    Perurena-Prieto, Janire
    Rodriguez-Bayona, Beatriz
    Martinez, Alba
    Ocana, Esther
    Molina, Juan
    [J]. IMMUNITY & AGEING, 2021, 18 (01)
  • [17] Martin MC., 2021, MEDRXIV2021042821256, pI, DOI [10.1101/2021.04.28.21256242, DOI 10.1101/2021.04.28.21256242]
  • [18] BCG vaccination in health care providers and the protection against COVID-19
    Netea, Mihai G.
    van der Meer, Jos W. M.
    van Crevel, Reinout
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (02)
  • [19] Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
    Noval, Maria G.
    Kaczmarek, Maria E.
    Koide, Akiko
    Rodriguez-Rodriguez, Bruno A.
    Louie, Ping
    Tada, Takuya
    Hattori, Takamitsu
    Panchenko, Tatyana
    Romero, Larizbeth A.
    Teng, Kai Wen
    Bazley, Andrew
    de Vries, Maren
    Samanovic, Marie, I
    Weiser, Jeffrey N.
    Aifantis, Ioannis
    Cangiarella, Joan
    Mulligan, Mark J.
    Desvignes, Ludovic
    Dittmann, Meike
    Landau, Nathaniel R.
    Aguero-Rosenfeld, Maria
    Koide, Shohei
    Stapleford, Kenneth A.
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [20] S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit
    Phuong Nguyen-Contant
    Embong, A. Karim
    Kanagaiah, Preshetha
    Chaves, Francisco A.
    Yang, Hongmei
    Branche, Angela R.
    Topham, David J.
    Sangster, Mark Y.
    [J]. MBIO, 2020, 11 (05): : 1 - 11